Comparative Pharmacology
Head-to-head clinical analysis: FERROUS FUMARATE versus TRIFERIC AVNU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERROUS FUMARATE versus TRIFERIC AVNU.
FERROUS FUMARATE vs TRIFERIC AVNU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron is an essential component of hemoglobin, myoglobin, and various enzymes; ferrous fumarate provides elemental iron for erythropoiesis and oxygen transport.
Triferic AVNU (ferric pyrophosphate citrate) is an iron replacement product that provides iron to hemoglobin synthesis without increasing circulating iron levels. It is taken up by transferrin and delivered to erythroid precursor cells for heme synthesis.
Oral: 200 mg (equivalent to 65 mg elemental iron) three times daily. Adults: 325 mg (106 mg elemental iron) one to three times daily.
Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.
None Documented
None Documented
5-7 hours for iron in serum after absorption; terminal half-life of storage iron (ferritin) is approximately 6 days; clinical context: follows first-order kinetics with iron recycling.
Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved.
Primarily fecal (about 90%) as unabsorbed iron; minor renal excretion (<1%) via sloughed intestinal cells and bile; negligible urinary elimination.
Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible.
Category C
Category C
Iron Replacement
Iron Replacement